<DOC>
	<DOCNO>NCT00025649</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell bone marrow transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy give surgery follow peripheral stem cell bone marrow transplantation treat infant newly diagnose neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Surgery Peripheral Stem Cell Bone Marrow Transplantation Treating Infants With Newly Diagnosed Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine survival infant newly diagnose stage II , III , IV , IVS neuroblastoma MYCN amplification treat etoposide , carboplatin , cyclophosphamide , doxorubicin , vincristine follow surgery busulfan melphalan autologous peripheral blood stem cell bone marrow transplantation . - Determine whether prognostic criterion could use future therapeutic stratification patient . OUTLINE : This multicenter study . Patients receive VP-CARBO chemotherapy comprise etoposide IV 2 hour carboplatin IV 1 hour day 1-3 . Treatment repeat every 21 day 2 course . Patients receive CADO chemotherapy comprise cyclophosphamide IV 1 hour day 1-5 , doxorubicin IV 6 hour day 4 5 , vincristine IV day 1 5 . Treatment repeat every 21 day 2 course . Patients receive filgrastim ( G-CSF ) subcutaneously daily 5 day . Patients undergo leukapheresis collect peripheral blood stem cell ( PBSC ) . Patients mobilize sufficient cell undergo bone marrow harvest . Patients eligible surgery undergo surgical resection . Patients stage IV disease less complete response metastatic disease initial chemotherapy remove study . Beginning within 2 week surgery , patient receive 1 additional course VP-CARBO chemotherapy follow 1 additional course CADO chemotherapy . After least 3 week , patient receive high-dose chemotherapy comprise busulfan IV 24 hour day -7 -3 melphalan IV day -2 . PBSC bone marrow reinfused day 0 . At least 2 month completion high-dose chemotherapy bone marrow PBSC transplantation , patient undergo radiotherapy primary site , accord preoperative imaging study . Patients treat oral tretinoin megatherapy . Patients follow within 6 month annually 5 year . PROJECTED ACCRUAL : A total 40 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose stage II , III , IV , IVS neuroblastoma ganglioneuroblastoma MYCN amplification ( i.e. , least 10 copy ) PATIENT CHARACTERISTICS : Age : Under 12 month diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>